In the blink of an eye, 2022 has reached the last month, and when it comes to the highlight of the pharmaceutical industry at the end of the year, a new round of national medical insurance negotiations is one of them
.
On the day of the opening of December, a friend from Pfizer China in the author's circle of friends updated the news, looking forward to a number of blockbuster drugs that have passed the preliminary review to enter medical insurance and benefit patients
as soon as possible.
A screenshot from the author's circle of friends
Piperoxiclib is the world's first marketed cyclin-dependent kinase (CDK) 4/6 inhibitor that can disrupt tumor cell proliferation
by restoring cell cycle control by inhibiting CDK4/6.
The product is an original Pfizer drug approved by the State Food and Drug Administration in July 2018 for the treatment of locally advanced or metastatic breast cancer
with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative.
Lolatinib is a targeted drug developed by Pfizer against ALK and ROS1 gene mutations, a 3rd-generation ALK inhibitor used for common tumor mutations and tumor brain metastases that can lead to resistance to current drugs, and can function
through the blood-brain barrier.
In February 2020, the product was approved for listing in Hong Kong, but has not yet been introduced
in the mainland.
In addition to the above products, Pfizer also has acute leukemia drugs for injection ogaituzumab, nematevir tablets/ritonavir tablets and other products in the list that have passed the preliminary form review
.
According to the preliminary formal review list of the national medical insurance catalog, 344 of the 490 declared drugs in the national medical insurance catalogue will pass the preliminary review in 2022, and these products may be greatly reduced in price
at the national medical insurance negotiation site.
From the preliminary review list, in addition to Pfizer's entry, there are also products of multinational pharmaceutical companies such as Novo Nordisk's diabetes treatment drug Degludec insulin liraglutide injection, Roche's emmetrituzumab for breast cancer, and Takeda's vebutuximab that once again hit the medical insurance catalog
.
The analysis believes that the reason behind the initiative of original drug companies to carry out medical insurance negotiations is partly due to the expiration of the patent of the original research product and the choice
under the impact of generic drugs.
For example, piperaciclib, the Chinese compound patent for piperaciclib will expire
on January 10, 2023.
At present, many pharmaceutical companies in China have laid out this blockbuster variety, including Qilu Pharmaceutical, Haosen Pharmaceutical, and Shanxiang Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical
.
In addition, many domestic pharmaceutical companies such as Simcere Pharmaceutical, Chongqing Yaoyou Pharmaceutical, Chia Tai Tianqing, Chuangnuo Pharmaceutical, Aishte Pharmaceutical, Daoen Pharmaceutical, Jilin Aodong, Kelun Pharmaceutical, and Aosaicom have submitted marketing applications for piperaciclib, and the original drug is facing a huge impact
on generic drugs.
However, original drugs are generally more expensive, and there are certain challenges
in negotiation.
The National Health Insurance Administration stressed that some of the more expensive drugs passed the preliminary formal review this year, only indicating that the drug met the declaration conditions and was eligible
to enter the next link.
Whether such drugs can eventually enter the national medical insurance drug catalogue also needs to be strictly reviewed in many aspects, including economy, and the exclusive drugs that pass the review must be negotiated, and non-exclusive drugs must be competitive, and only successful negotiations or bidding can be included in the catalog
.
Since 2018, the negotiation of the access to the national medical insurance drug list has been carried out for four consecutive years, and a total of 250 innovative and life-saving drugs have been added to the list through negotiation, with an average price reduction of more than 50%.
It is reported that in 2021, a total of 140 million people will be reimbursed for 221 negotiated drugs during the agreement period, reducing the burden of patients by 149.
49 billion yuan
.
According to the National Medical Security Administration's "China Medical Insurance", negotiations on the access of the 2022 medical insurance drug catalogue will officially start
in early December.
The new year's health insurance negotiation drama is about to begin, we wait and see!
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
